Stem Point Capital LP Autolus Therapeutics PLC Transaction History
Stem Point Capital LP
- $378 Billion
- Q1 2024
A detailed history of Stem Point Capital LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Stem Point Capital LP holds 2,965,721 shares of AUTL stock, worth $11.7 Million. This represents 5.0% of its overall portfolio holdings.
Number of Shares
2,965,721
Previous 451,375
557.04%
Holding current value
$11.7 Million
Previous $2.91 Billion
550.92%
% of portfolio
5.0%
Previous 0.78%
Shares
2 transactions
Others Institutions Holding AUTL
# of Institutions
122Shares Held
167MCall Options Held
411KPut Options Held
67.6K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$83.9 Million90.76% of portfolio
-
Blackstone Inc New York, NY20.5MShares$80.5 Million0.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$60 Million3.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$48.5 Million0.95% of portfolio
-
Wellington Management Group LLP Boston, MA10.8MShares$42.3 Million0.01% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $357M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...